Log in
Enquire now
‌

US Patent 10100129 Antibodies against CD73 and uses thereof

Patent 10100129 was granted and assigned to Bristol-Myers Squibb on October, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Bristol-Myers Squibb
Bristol-Myers Squibb
0
Current Assignee
Bristol-Myers Squibb
Bristol-Myers Squibb
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
101001290
Patent Inventor Names
Sandra V. Hatcher0
Haichun Huang0
Aaron P. Yamniuk0
Alan J. Korman0
Angela Goodenough0
Bryan C. Barnhart0
Emanuela Sega0
Guodong Chen0
...
Date of Patent
October 16, 2018
0
Patent Application Number
155206380
Date Filed
November 19, 2015
0
Patent Citations Received
‌
US Patent 11673894 Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
0
‌
US Patent 11692042 Anti-CD73 antibodies and methods of use thereof
0
‌
US Patent 11312783 Antibody molecules to CD73 and uses thereof
0
‌
US Patent 12024565 Targeted CD73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
0
‌
US Patent 12060433 CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy
0
‌
US Patent 12018089 Anti-CD73 antibodies and uses thereof
0
‌
US Patent 11352440 Antibodies against CD73 and uses thereof
0
‌
US Patent 11873304 Fused pyrimidine derivatives as A2A/A2B inhibitors
0
...
Patent Primary Examiner
‌
Laura B Goddard
0
Patent abstract

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10100129 Antibodies against CD73 and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.